Type B insulin resistance syndrome induced by anti‐PD‐1 therapy.

This article discusses a case study of a 59-year-old man who developed type B insulin resistance syndrome (TBIRS) after receiving anti-PD-1 therapy for Hodgkin lymphoma. The patient initially developed fulminant type 1 diabetes after starting treatment with sintilimab, and later presented with severe insulin resistance. TBIRS is a rare and challenging condition with a poor prognosis. This case highlights the need for further research and attention to immune-related adverse effects of anti-PD-1 therapy. The authors of the article conducted the study and provided the clinical diagnoses and treatments. No conflicts of interest were reported, and the research was conducted without any commercial or financial relationships. [Extracted from the article]